« Back

AVI BioPharma - Investor and Analyst Breakfast

09/08/08 2:49 PM EDT

Transitioning an Antisense Pioneer into a Leading RNA–based Drug Discovery and Development Company

September 10, 2008.  Harvard Club NYC 07.30 — 10.30 a.m.

Dr. Leslie Hudson, President and CEO, AVI BioPharma
RNA–based drug discovery and development

Professor Francesco Muntoni, Professor of Pediatric Neurology, Head of the Dubowitz Neuromuscular Centre, University College London Institute of Child Health, London, UK
Duchenne Muscular Dystrophy (DMD): The disease, its clinical management and future treatment

Dr. Leslie Hudson
Clinical Trials of AVI–4658 and the commercial prospects for a DMD franchise

Dr. Ryszard Kole, SVP of Discovery Research, AVI BioPharma
Directed alternative splicing mediated by novel oligomers with increased potency and bioavailability

Benjamin D. Johnson, Engineering Manager, Global Therapeutics, a COOK Medical Company
Developing a breakthrough drug–eluting stent (DES) technology using the GTX platform and an improved application of antisense therapy: AVI–5126

Dr. Patrick Iversen, SVP of Strategic Alliances, AVI BioPharma
Biodefense priorities for AVI and the enablement of HCV drug discovery

J. David Boyle, SVP Finance and CFO, AVI BioPharma
Building an RNA–based drug discovery and development company

General Q&A

Meeting ends 10.30 a.m. EDT


This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.